




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領
文檔簡介
PrecursorsoftheGynecologicTract:fromtheCervixtotheFallopianTube"Pathogenesis1.HPV-relatedneoplasms:MonoclonalselectionandatypiaareconcurrentwithHPVinfectionClonalselectionandatypiaoccurintandemwithgeneticmutations.Clonalselectionthateventuallyleadstomalignancypredatesmorphologicatypia.ThreeModelsofPrecursorDiseaseCervixHPVoncogenictransformationEndometriumpTENmutationsTubo-OvarianP53+BRCATheCervicalTransformationZoneAnarrowcircumferentialzoneofsquamo-columnartransition.IsthesiteoforiginforHPVrelatedcervicalneoplasiaEctocervixT-ZoneEndocervixTheCervicalTransformationZoneEcto Endo ReserveCellsp63Nl CIN1CIN2CIN3 LSIL HSIL HSILRisk1%5%12%20%HPV1610%45%68%SquamousIntraepithelialLesions“Easy”LSILsExophyticcondylomaFlatcondyloma(CIN1)ExophyticCondyloma(CINI)ExophyticarchitectureParabasalexpansionMildbasalatypiaPreservedpolarityViralcytopathiceffectLowmitoticindexLowriskHPVtypesFlatCondyloma(CINI)FlatarchitectureTypicallyassociatedwith“intermediate”orhighriskHPVtypes“Easy”HSILsClassicCIN2-CIN3KoilocyticHSILKeratinizingHSILKoilocyticHSIL
(CIN2)ProminentkoilocyteswithconspicuousatypiaParabasalcellnuclearenlargement,molding,lossofpolarity,hyperchromasiaorabnormalmitosesCINIIIFullthicknessatypiaImmatureKeratinizingHSILProminentsuperficialparakeratosiswithconspicuousatypia,anisokaryosisandhyperchromasiaParabasalcellatypiamaybesubtleThe“Metaplastic”SILsImmaturemetaplasticLSILsassociatedwithLRHPVs(immaturecondyloma)Semi-maturemetaplasticSILs(Eosinophilicdysplasia)ImmaturemetaplasticSILs(HSIL)StratifiedvariantsofAIS(SMILEs)HPVCellTropismsandLesionsTransformationZone Ectocervix
IndifferentSquamousColumnarSquamous
HPV16/18
HPV6
HPV16
HPV6HPV16/18
HSIL ImmatureMetapl SMILEACIS LSILACISLSILHSILImmatureCondyloma
(PapillaryImmatureMetaplasia)SlenderpapillaelinedbyimmaturemetaplasticepitheliumLowmitoticindexRegularnuclearspacingwithnucleoliLowtomoderateKi-67indexLowriskHPVtypesImmatureCondyloma(LSIL)PapillaeMinimalatypiaImmatureCondyoma(LSIL)EosinophilicDysplasia(CIN1-2)Zhengetal,2004Immature“metaplastic”HSIL(CIN3)SMILE(StratifiedAIS)StratifiedEndocervicalCellsImplicationsImmaturecondyloma–benign,butexcludeco-existingHSILEosinophilicdysplasia–CIN1-2Metaplastichighgrade–CIN3SMILE–AdenocarcinomainsituNormalLSILHSILMolecularDiagnosisofCervicalNeoplasiaHPVnucleicacidtestingtodetermineriskHostbiomarkersassurrogatesofHPVCellcycleandHPVcyclinsandotherbiomarkersAtrophy+HSILMiB1 p16MiB1 p16HSIL(immaturemetphenotype)MiB1 p16ReactiveProspectiveRiskof≥CIN3(1)Follow-uptime(years)
123456789
10
11Cumulativeincidencerate(%)05101520HPV16+HPV18+HC2+HRHPV-PortlandKhanetal.,JNCIIntheVaccineEraThemostimportantHPVswouldbeneutralizedParadigmsofscreeningandmanagementwouldbemoreconservative?RoleofHPVtestingvsotherparameters.ClassificationSystemsandManagementofPre-invasiveSquamousCellLesionsoftheCervix1960s1970-80s1990sMild ModerateSevereCISCondyloma/CIN1 CIN2CIN3
LSIL HSIL HSILFollow Cone/HysterectomyCryotherapyLaser/ConeFollowLEEPFuture?
LSIL(-)HPV16 greyzone HSIL+HPV16
FollowLEEPHPVInfectionHSILACISSquamousCellCaAdenocarcinomaEndometrialCarcinoma30,000cases,10,000deathsperyearNotreadilydiagnosedbyPapsmearTargetsendometrialliningepitheliumPersistentestrogenstimulationAbnormalbleedingPrecursorlesion(EndometrialintraepithelialneoplasiaorEIN)AnovulatoryPremalignantMalignantEstrogenMutation→ClonalAggressiveCarcinomaEINBenignGeometryof
Benign,Premalignant,andMalignantlesionsSurfaceRepairRepair“RegularlyIrregular”G.L.MutterG.L.MutterEIN
ArchitectureAreaofGlands>Stroma(VPS<55%)
CytologyCytologydiffersbetweenarchitecturallycrowdedfocusandbackground.
Size>1mmMaximumlineardimensionexceeds1mm.
ExcludemimicsBenignconditionswithoverlappingcriteria:ExcludeCancerCarcinomaifmazelikeglands,solidareas,orsignificantcribriforming
EIN(AtypicalHyperplasia)EINCytologicDemarcationEINVariant(intraglandularcomplexity)VolumePercentageStromaInEIN,AreaofGlands>Stroma0102030405060708090100Baak,Mutter,andJanssen2000-2002CancerNoCancern=297MonoclonalPolyclonaln=940500100015002000FollowupInterval,DaysCHWACHWOASHWOAHyperperplasiaDx0500100015002000NoCancerCancerOutcomeFollowupInterval,DaysBenign,
Non-EINEINEINDxHechtetal,2005Clinicaloutcomesof97endometrial“hyperplasias”byWHOandEINsubjectiveDiagnosisPTENandEndometrialCancerAlsoknownasMMAC-1orTEP-1ActsviaAkt-dependentpathwaytosuppresscelldivisionHighfrequencyofmutationinEIN(60%)Notadiagnosticmarker,buthashelpedtodefineEINEINProliferativeG.L.MutterPTENG.L.MutterProliferative EINDifferentialDiagnosisofEINArtifactsofcrowdinginproliferativeandsecretoryendometriumMildglandcrowdinginpolypsMixedpatternsduetoclonaldiversityPolypClonalMixedPatternClonalMixedPatternClonalMixedPatternSecretoryEINSecretoryEINLossofPTENExpressionpriortoNeoplasia(LatentPrecursor)Proliferative EIN AnovulatoryG.L.MutterEndometrioidPrecursorsLossofpTENisacommonmarkerforprecursors(EIN)ThesamemutationmaypredateEIN(LatentPrecursors)Aremutationscommonintheadultendometrium?YesPersistentestrogenstimulationselectsforpTENandsubsequentmutations.G.L.MutterTreatmentofLatentPrecancersOrboetal(CancerResearch2006)Frequencyoflatent(pTENnullglands)wascomputedbeforeandaftertherapywithprogestin-coatedIUDTherapyreducedrateofpersistentlatentprecursorsfrom62and5percentrelativetountreatedwomen.SummaryDiagnosisofEINbasedonreproduciblecriteriaLatentprecursorexistswhichmaybepreventablePrecursorstoserouscarcinomaarestillunderinvestigationThePathogenesisofOvarianCancer25,000cases/12,000deathsperyearMostdifficulttoidentifyearlybecauseoflocationTraditionallyassumedtooccurincorticalepithelialcystswithintheovaryDirecttransformationofthesurfacemesothelium/epitheliumoftheovaryTransportfromthefallopiantubeTransportfromtheuterus(endometriosis)CorticalInclusionCystsOvarianCarcinomasPathogenesisSometumorsappeartoarisefrominclusioncysts,suchasendometrioidcarcinomas(fromendometriosis)ormucinouscystadenocarcinomas.Theoriginofthemostlethalcarcinomas(serous)hasbeenlessclear.HighGradeSerousCarcinomaBRCAasaModelforEarlyOvarianCancerUpto50%ofwomenwithBRCAmutations(BRCA+)willdevelopepithelialovariancancerOpportunitytoevaluatethetubesandovariesinwomenwhoundergoprophyacticsalpingo-oophorectomyanddetecttumorsearlyintheircourseColgan2001,Leeper2002,Powell2005,Finch2005,Cass2005,Medeiros2006
DistributionofEarlySerousCarcinomainBRCA+WomenAuthor
No.
Tumor(%)
Tubal
(%tumors)Leeper’02305(17)3(60)Powell’05 677(10) 4(57)Finch’061597(4) 6(86)BWH’05-071407(5)7(100)SEE-FIMProtocolSectioningandextensivelyexaminingthefimbriatedendBasedonthehypothesisthatthefimbriatedendisuniqueandsusceptibletotubalneoplasiaMedeirosetal2006p53SerousTubalIntraepithelialCarcinoma(STIC)Acommonearlyserouscarcinomadetectedin~5%ofBSOsfromBRCA+WomenPathogenesisinBRCA+Women85+%ofcarcinomasdetectedearlyinBRCA+womenoriginateinthedistalfallopiantube.Thedistalfallopiantubeisthepreferredsiteforalltubalcarcinomas,irrespectiveofBRCAstatusMedeirosetal2006,Cassetal2005,Finchetal2006Do“Ovarian”SerousCarcinomasActuallyAriseintheDistalTube?Findings~70ConsecutiveserouscarcinomasOnehalfoftumorsclassifiedasovarianorperitonealcarcinomaswereassociatedwithanearlycarcinoma(STIC)inthefimbria.10of10casesanalyzedcontainedidenticalp53mutationsintubalandovarian/peritonealneoplasmsKindelbergeretal2007,Carlsonetal,submittedOvarianserouscarcinomaandseroustubalintraepithelialcarcinoma(STIC)“Ovarian”CarcinomaCoexistingovarianserouscarcinomaandseroustubalintraepithelialcarcinoma(STIC)thatsharedidenticalp53mutationsTubalintraepithelialcarcinomaassociatedwith“primaryperitonealserouscarcinoma”TwopathwaysforthedevelopmentofovarianserouscarcinomaPelvicCarcinomainBRCA+WomenSymptomaticvsAsymptomatic
Piek’03 Medeiros’06K’berger’07Carlson(unpub)APecursortoPelvicSerousCarcinomaShouldbecommonShouldbeinthesamelocationasthecancerShouldarisefromthesamecelltypeShouldfulfillsomebutnotallofthebiologicattributesofmalignancyShouldsharesomeofthesameriskfactorsascarcinomaShouldbeseenincontinuitywithmalignancyp53Signatures(latentprecursors)STIC BenignMucosaH&E p53 H&E p53Immuno-localizationofp53protein(associatedwithmutation)canbefoundinbothearlyserouscarcinomasandbenigntubalmucosa(p53signatures)“p53Signature”Intensep53nuclearaccumulationinnon-neoplastictubalmucosaLeeetal2006P53SignaturesTheTubal“p53Signature”isaPrecursortoPelvicSerousCarcinomaInthismodel,theproposedprecursor(p53signature)sharesthefollowingwithserouscarcinoma:Involvessecretorycells(BCL-2+,HMFG2+)Predominatesinthedistalfallopiantube(fimbria)ExhibitsevidenceofDNAdamage(γ-H2AX)Frequentp53mutationsbyLCManddirectsequencingEvidenceoftransitionlesions(TILTs)SeenincontinuitywithSTIC.SimilarepidemiologicprofileasovariancancerLee,Miron,etal2007SecretorycellP53SignatureTILTSTICInvasionTubeOvarySerous(surface)CarcinomaOvulationPeritonealCarcinomaOxidativestressInitiatorDNADamageP53mutationPromotor(BRCA+)GrowthdisregulationStratificationExfoliation?SerousCarcinogenicSequenceintheFimbriaH&Ep53MiB1H&Ep53MiB1H&EMiB1ClonalP53mutationClonalP53mutation+expansionClonalP53mutation+expansion+proliferationClonalP53mutation+expansion+proliferation+lossofpolarity+exfoliationLatentprecursor(p53signature)LesionintransitionIntraepithelialCAStepI StepII StepIIIJarboeetal,2007(IntJGynecolPatholinpress)BRCA+WomenApproximately5%ofmutation-positivewomenwillharboranearlymalignancyintheirprophylacticspecimen.Mostwillbelocatedinthedistaltube.Mostwillbenon-invasive(STIC)ExaminationofovariansurfacesessentialMustbedistinguishedfromnormalmucosa.SpectrumofSTICCommonvariablesLossofepithelialcellpolarity,fractures,exfoliationNuclearenlargement,nucleoliHomogeneouscelltype,absenceofciliaP53+(80-90%)HighMIB1indexVariantsNon-stratifiedDegenerativeFallopianTube(STIC)STICTIC TICTIC NormalTICSTICfromPatientPreviouslyTreatedforBreastCAObserverReproducibilityforSTICFor12reviewers=0.333Forpathologyresidents=0.253Forexperiencedgynecologicpathologists=0.453ItishighlyadvisabletocorroboratethisdiagnosiswithanotherobserverCarlsonetal2008BenignSalpingealEpitheliumHeterogeneous,normalnuclearmorphologySerousTubalIntraepithelialCarcinomaHomogeneous,abnormalnuclearmorphologyProblematicLesionsTubalintraepitheliallesionsintransition(TILT).Maintenanceofpseudo-stratifiedepitheliumMixtureofciliatedandsecretorycellsModerateMIB1immunoreactivityShouldbereviewedbymorethanoneobserverifnecessarytoexcludeSTICThereportshouldstateclearlythatthelesionisorisnotdiagnosticofSTIC
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 集成電路板生產(chǎn)流程
- 協(xié)議離婚后同居是不是受法律保護
- 車輛贈與合同范例
- 建筑企業(yè)戰(zhàn)略合作協(xié)議
- 車輛衛(wèi)生制度管理制度
- 足浴會所銷售管理制度
- 裝卸公司條件管理制度
- 提升工程20管理制度
- 貿(mào)易公司集中管理制度
- 連鎖餐廳樓面管理制度
- 品管圈PDCA獲獎案例-提高保護性約束使用的規(guī)范率醫(yī)院品質(zhì)管理成果匯報
- FOCUS-PDCA品管工具改善案例-手術(shù)室與外科病區(qū)提高手術(shù)患兒交接過程正確率成果匯報
- 勞動力材料投入計劃及保證措施機械設備投入計劃
- 《吸光度與透過率》課件
- 《中國膿毒血癥指南》課件
- 工程信息轉(zhuǎn)讓合同范例
- 中國頭痛門診建設專家共識2024(全文)
- 研學基地與旅行社合作協(xié)議書
- 得表揚了課件
- 2023年中國鐵路南寧局集團有限公司招聘考試真題
- 《冠心病病人的護理》課件
評論
0/150
提交評論